Cambridge’s biotech ecosystem is built on progression – from early discovery through to scale. 
As TRIMTECH expands out of the Milner Therapeutics Institute’s Bio-incubator and into the Babraham Research Campus, we are pleased to reflect on their journey so far.
TRIMTECH is focused on neurodegenerative and inflammatory diseases, such as Alzheimer’s, Parkinson’s and Huntington’s – where there’s still a huge unmet need. One of the big challenges in these diseases is the build-up of toxic proteins inside cells, which has proven difficult to tackle with traditional drugs. TRIMTECH’s approach is a bit different. Instead of trying to block or modify these proteins, they’re working on selectively removing them using targeted protein degradation. The key idea is to get rid of the harmful parts without interfering with normal protein function, which could make a real difference to both safety and effectiveness.
Gaining momentum in the Milner Therapeutics Institute’s Bio-incubator
TRIMTECH began its journey in the Milner Bio-incubator, which offers a unique environment on the Cambridge Biomedical Campus for companies to work with other startups, pharma and academic scientists in a space that is designed to spark collaboration. Being embedded in that network gave TRIMTECH early access to both scientific insight and industry perspective – something that can be difficult to replicate outside a setting like the Milner Institute. The Bio-incubator offers not only modern lab space but access to equipment, expertise, and potential collaborators that can make a huge difference for growing companies. For TRIMTECH, the Milner environment supported the company as it established itself in the ecosystem, grew its team, and prepared for the next stage of growth.
In 2025, TRIMTECH raised a $31 million seed round, one of the largest in Europe, with backing from investors including Cambridge Innovation Capital and the Dementia Discovery Fund. The impressive seed funding led to TRIMTECH being named as one of Fierce Biotech’s ‘2025 Fierce 15’. The investment is allowing the company to develop its growing pipeline of potent, CNS (central nervous system)-penetrant therapeutics based on its aggregate-selective degrader molecules, known as TRIMTAC®. Building on two decades of academic research, TRIMTECH is leveraging the E3 ubiquitin ligase TRIM21 to selectively and potently degrade protein aggregates associated with a range of diseases. Using this novel approach, the company is developing small molecule medicines for severe neurodegenerative and inflammatory disorders that address the needs of large patient populations who currently have limited treatment options.
Scaling at the Babraham Research Campus
TRIMTECH’s move to Babraham is the next big step in the company’s journey. Building on the foundations established at Milner, they now have space that can support a growing team and more advanced research, and the move puts them in the middle of one of the UK’s most active biotech communities, surrounded by other startups and scale-ups going through similar phases of growth.
What TRIMTECH’s story shows is that Cambridge isn’t just about great science in isolation. It’s about the pipeline – from academic discovery at the LMB, and the UK Dementia Research Institute at the University of Cambridge, to early-stage funding, translational environments like the Milner Therapeutics Institute, to scale-up space. Each part plays a role, and when it works well, companies like TRIMTECH can move through the system at speed.
TRIMTECH has proven to be a force in the industry. They have a clear scientific approach, strong backing, and are addressing a clear unmet need. Their platform is well placed to have a real impact not only for neurodegenerative diseases, but for the wider field of targeted protein degradation. This move marks an important inflection point on TRIMTECH’s journey, and we wish the team the very best for the next stages of their journey.